[EN] NMDA RECEPTOR MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DES RÉCEPTEURS NMDA ET UTILISATIONS DE CEUX-CI
申请人:CADENT THERAPEUTICS
公开号:WO2018119374A1
公开(公告)日:2018-06-28
Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
[EN] NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX DÉRIVÉS DE THIÉNOPYRIMIDINE, PROCÉDÉ POUR LEUR PRÉPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
申请人:SERVIER LAB
公开号:WO2015097123A1
公开(公告)日:2015-07-02
Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description.
Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
申请人:——
公开号:US20040259882A1
公开(公告)日:2004-12-23
The invention relates to triazole compounds of the general formula I
1
wherein
R
1
is hydrogen or methyl, and
R
2
is C
3
-C
4
alkyl or C
1
-C
2
fluoroalkyl,
as well as the physiologically tolerated acid addition salts of these compounds.
The invention also relates to a pharmaceutical composition that comprises at least one triazole compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D
3
receptor antagonists or dopamine D
3
agonists, said method comprising administering an effective amount of at least one triazole compound or physiologically tolerated acid addition salt of the formula I to a subject in need thereof.
[EN] 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR<br/>[FR] COMPOSÉS DE 4-PIPÉRAZINYLPYRIMIDINE CONVENANT POUR TRAITER DES TROUBLES QUI RÉPONDENT À UNE MODULATION DU RÉCEPTEUR D3 DE LA DOPAMINE
申请人:ABBOTT GMBH & CO KG
公开号:WO2006015842A1
公开(公告)日:2006-02-16
The present invention relates to novel 4-piperazinylpyrimidine compounds. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor. The 4 piperzinylpyrimidine compounds have the general formula (I), wherein Ar, X, A, R1 and R1a are as defined in the claims.